|
|
|
|
| LEADER |
01894nam a2200277 u 4500 |
| 001 |
EB001839954 |
| 003 |
EBX01000000000000001003943 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Foam sclerotherapy for treatment of varicose veins
|h Elektronische Ressource
|b a review of the clinical effectiveness, safety, cost-effectiveness, and guidelines
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa
|b Canadian Agency for Drugs and Technologies in Health
|c 12 February 2015, 2015
|
| 300 |
|
|
|a 1 PDF file (47 pages)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Comparative Effectiveness Research
|
| 653 |
|
|
|a Varicose Veins / therapy
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a Sclerosing Solutions / therapeutic use
|
| 653 |
|
|
|a Sclerotherapy / methods
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK349766
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Constant evolution in techniques to treat varicose veins has been driven by the need for: better patient comfort, reduced side effects and the desire for better and longer-lasting clinical results. New developments towards foam sclerotherapy (FS) warrant questions regarding their clinical and economic evidence. The purpose of this review is therefore to compare the available evidence on FS for patient with varicose veins compared with alternative treatment modalities (i.e., surgery, endovascular thermal ablation, or liquid sclerotherapy) in terms of their comparative clinical effectiveness, safety, cost-effectiveness, and evidence-based guidelines
|